Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study-Reference-Cited by-同舟云学术

Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study

Published:2024-09 Issue:9 Volume:24 Page:1015-1024
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Falsey Ann R,Hosman Tessa,Bastian Arangassery Rosemary,Vandenberghe Sjouke,Chan Eric K H,Douoguih Macaya,Heijnen Esther,Comeaux Christy A,Callendret Benoit,Allaw Mohammed,Briskin Toby,Brune Daniel,Egelhof Richard,Ervin John,Falsey Ann,Fierro Carolos,Fried David,Jackson-Booth Peta-Gay,Kimmel Murray,McGill Lorrie,Nugent Paul,Patel Suchet,Rizzardi Barbara,Ruhlmann James,Strout Cynthia,Tharenos Leslie,Vachris Timothy,Wadsworth Tyler

Publisher

Elsevier BV

Reference30 articles.

1. Respiratory syncytial virus infection in adults;Nam;BMJ,2019

2. Respiratory syncytial virus infection in elderly and high-risk adults;Falsey;N Engl J Med,2005

3. Change in functional status associated with respiratory syncytial virus infection in hospitalized older adults;Branche;Influenza Other Respir Viruses,2022

4. LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study

5. Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study;Hartnett;Influenza Other Respir Viruses,2022

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The long-term efficacy of a respiratory syncytial virus vaccine for older adults;The Lancet Infectious Diseases;2024-09

2. Vaccines for Respiratory Viruses—COVID and Beyond;Vaccines;2024-08-22

3. Advocating for inclusive respiratory syncytial virus vaccine trials to address health disparities;The Lancet Infectious Diseases;2024-08